Sartorius Stedim Biotech SA / Mot-clé(s) : Assemblée générale Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A. 25-Mars-2025 / 15:35 CET/CEST Aubagne, le 25 mars 2025 Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A.Lors de l'Assemblée générale annuelle mixte de Sartorius Stedim Biotech S.A. qui s'est tenue aujourd'hui, les actionnaires à une large majorité ont donné décharge à tous les administrateurs.Les actionnaires ont élu Cécile Dussart et Christopher Nowers en tant que nouve...
Sartorius Stedim Biotech SA / Key word(s): AGM/EGM Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. 25-March-2025 / 15:35 CET/CEST Aubagne, France | March 25, 2025 Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed...
Sartorius Stedim Biotech SA / Key word(s): Annual Results Sartorius Stedim Biotech releases Universal Registration Document 2024 17-Feb-2025 / 10:02 CET/CEST Aubagne, France | February 17, 2025 Sartorius Stedim Biotech releases Universal Registration Document 2024Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2024 including the Annual Financial Report. The document is available at the following link: Financial calendar March 25, 2025 Annual Shareholders’ Meeting April 16, 2025 ...
Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat annuel Sartorius Stedim Biotech publie son Document d’Enregistrement Universel 2024 17-Fév-2025 / 10:02 CET/CEST Aubagne, le 17 février 2025 Sartorius Stedim Biotech publie son Document d’Enregistrement Universel 2024Sartorius Stedim Biotech, partenaire de premier plan de l’industrie biopharmaceutique, a publié aujourd’hui son Document d‘Enregistrement Universel 2024 incluant le rapport financier annuel. Le document est disponible à l’adresse suivante : Agenda financier 25 mars 2025 Assemblée générale annuelle de...
Sartorius Stedim Biotech SA / Mot-clé(s) : Dividende Le Conseil d’administration de Sartorius Stedim Biotech décide de proposer un dividende de 0,69 euro par action à l’Assemblée générale annuelle des actionnaires 07-Fév-2025 / 15:57 CET/CEST Aubagne, le 7 février 2025 Le Conseil d’administration de Sartorius Stedim Biotech décide de proposer un dividende de 0,69 euro par action à l’Assemblée générale annuelle des actionnaires Cécile Dussart et Christopher Nowers candidats à l'élection au Conseil d'administration lors de la prochaine Assemblée générale des actionnaires Le Consei...
Sartorius Stedim Biotech SA / Key word(s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 / 15:57 CET/CEST Aubagne, February 7, 2025Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting Cécile Dussart and Christopher Nowers nominated for election to the Board of Directors at the upcoming Shareholders’ Meeting The Board of Directors of Sartorius Stedim Biotech S.A. resolved at its meeting to submi...
Der scheidende CEO plant die 1. Guidance FY 25 nur qualitativ und in „bewusst vorsichtigem Grundton“ (Konkretisierung am 16.04.25). Die Visibilität „werde besser“. Lagerabbau und Investitionszurückhaltung seien in Q4/24 überwunden, ein stabiles positives Momentum sei aber noch nicht erkennbar.
The outgoing CEO plans to give only a qualitative outlook for the first time in FY 25 and in a “deliberately cautious tone” (more details on April 16, 2025). Visibility “will improve”. Inventory reductions and investment restraint were overcome in Q4/24, but a stable positive momentum is not yet visible.
We upgrade Stedim to Hold after a strong Q4 order book and signs of improvement across the bioprocessing industry. Whilst the Stedim valuation seems very stretched to us, we feel comfortable sales can grow HSD this year with a 2% FX tailwind, improving order book & signs that many customers are now back to normal ordering patterns. Our proprietary biologic demand model shows that demand should grow 9% this year but is slowing over the coming years & our yield analysis shows that improving yields...
Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat annuel/Résultat trimestriel Sartorius Stedim Biotech publie ses résultats préliminaires non audités pour l’exercice 2024 28-Jan-2025 / 07:04 CET/CEST Aubagne, France | 28 janvier 2025Sartorius Stedim Biotech publie ses résultats préliminaires non audités pour l’exercice 2024 Chiffre d’affaires à 2 780 millions d’euros, soit, à taux de change constant1 une hausse de 0,6 % en tenant compte de la contribution non-organique2(déclaré : + 0,2 % ; organique : -0,7 % à taux de change constant1) EBITDA courant1 à 779 millions d’euros,...
Sartorius Stedim Biotech SA / Key word(s): Annual Results/Quarter Results Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 28-Jan-2025 / 07:04 CET/CEST Aubagne, France | January 28, 2025Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 Sales revenue at 2,780 million euros, in constant currencies1 up +0.6 percent including non-organic contribution2, (reported: + 0.2 percent, organic1: - 0.7 percent in constant currencies) Underlying EBITDA1 of 779 million euros, resulting margin at 28.0 percent; net profit of 175 ...
The recovery in growth in the IT & engineering services sector is undermined by the still mixed macroeconomic climate and the setbacks in the automotive and aerospace sectors. The improvement in sector momentum will therefore be minimal in H2 2024 with a growing decorrelation between the US which should be robust and a stagnating Europe. This leads us to adopt a more cautious approach on companies in our sector (revision to our 2025 growth estimates for 12 companies) and to prefer Acc...
La reprise de la croissance du secteur IT & Engineering Services est mise à mal par un contexte macro toujours mitigé et par les déboires des secteurs Auto et Aéro. Ainsi, l’amélioration de la dynamique du secteur sera minimale au S2 2024 et probablement aussi au S1 2025, avec une décorrélation grandissante entre les US qui devraient être solides et une Europe stagnante. Ceci nous amène à adopter une approche plus prudente pour les sociétés de notre secteur (révision de croissance 202...
>The end of destocking, consumables drive recovery - While Q3 revenues were slightly lower than expected, the company highlighted that most customers are progressing well with their destocking programmes. The growing demand in theconsumables business more than compensates for still muted equipment demand. From a regional perspective, EMEA shows a positive development driven by the consumable business. The Americas still suffer from a high comparable base as well ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.